Redox control of vascular biology

Milan Obradovic\textsuperscript{1} | Magbubah Essack\textsuperscript{2} | Sonja Zafirovic\textsuperscript{1} | Emina Sudar-Milovanovic\textsuperscript{1} | Vladan P. Bajic\textsuperscript{1} | Christophe Van Neste\textsuperscript{2} | Andreja Trpkovic\textsuperscript{1} | Julijana Stanimirovic\textsuperscript{1} | Vladimir B. Bajic\textsuperscript{2} | Esma R. Isenovic\textsuperscript{1}

\textsuperscript{1}Laboratory of Radiobiology and Molecular Genetics, Vinca Institute of Nuclear Sciences, University of Belgrade, Belgrade, Serbia
\textsuperscript{2}King Abdullah University of Science and Technology (KAUST), Computational Bioscience Research Center (CBRC), Computer, Electrical and Mathematical Sciences and Engineering Division (CEMSE), Thuwal, Kingdom of Saudi Arabia

Correspondence
Milan Obradovic, Laboratory for Radiobiology and Molecular Genetics, Vinca Institute of Nuclear Sciences, University of Belgrade, P.O. Box 522, 11000 Belgrade, Serbia.
Email: obradovicmilan@hotmail.com
Magbubah Essack, King Abdullah University of Science and Technology (KAUST), Computational Bioscience Research Center (CBRC), Computer, Electrical and Mathematical Sciences and Engineering Division (CEMSE), 4700 KAUST, Thuwal 23955-6900, Kingdom of Saudi Arabia.
Email: magbubah.essack@kaust.edu.sa

Funding information
KAUST Office of Sponsored Research, Grant/Award Numbers: FCC/1/1976-17-01, FCC/1/1976-24-01; King Abdullah University of Science and Technology Base Research Fund, Grant/Award Number: BAS/1/1606-01-01; KAUST, Grant/Award Number: O5R#4129; Ministry of Education, Science and Technological Development, Republic of Serbia, Grant/Award Numbers: 173034, 173033

Abstract
Redox control is lost when the antioxidant defense system cannot remove abnormally high concentrations of signaling molecules, such as reactive oxygen species (ROS). Chronically elevated levels of ROS cause oxidative stress that may eventually lead to cancer and cardiovascular and neurodegenerative diseases. In this review, we focus on redox effects in the vascular system. We pay close attention to the subcompartments of the vascular system (endothelium, smooth muscle cell layer) and give an overview of how redox changes influence those different compartments. We also review the core aspects of redox biology, cardiovascular physiology, and pathophysiology. Moreover, the topic-specific knowledgebase DES-RedoxVasc was used to develop two case studies, one focused on endothelial cells and the other on the vascular smooth muscle cells, as a starting point to possibly extend our knowledge of redox control in vascular biology.

KEYWORDS
cardiovascular diseases, cardiovascular system, reactive oxygen species, redox

Abbreviations: Ang II, angiotensin II; AP-1, activator protein; CVD, cardiovascular disease; EC, endothelial cells; EGFR, epidermal growth factor receptor; ET-1, endothelin-1; H\textsubscript{2}O\textsubscript{2}, hydrogen peroxide; MMP, matrix metalloproteinase; NF-κB, nuclear factor-kappaB; NO, nitric oxide; ONOO\textsuperscript{−}, peroxynitrite; OxS, oxidative stress; PDGF, platelet-derived growth factor; PDGF-B, platelet-derived growth factor receptor beta; PTK, protein tyrosine kinases; PTP, protein tyrosine phosphatase; ROS, reactive oxygen species; SHR, spontaneously hypertensive rats; SM-MHC, smooth muscle-myosin heavy chain; TF, tissue factor; TF-FVIIa, tissue factor-FVIIa; TFPI, tissue factor pathway inhibitor; t-PA, tissue-type plasminogen activator; u-PA, urokinase-type plasminogen activator; VSMC, vascular smooth muscle cells; XO, xanthine oxidase.

Milan Obradovic and Magbubah Essack contributed equally to this study.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2019 The Authors. BioFactors published by Wiley Periodicals, Inc. on behalf of International Union of Biochemistry and Molecular Biology.
INTRODUCTION

Reactive oxygen species (ROS) and reactive nitrogen species (RNS) stimulate redox homeostasis mechanisms, and thus, they are considered critical signaling molecules for maintaining cellular homeostasis. However, these signaling molecules can be harmful, as well. That is, when ROS/RNS formation outpaces the ROS/RNS removal processes, oxidative stress (OxS) occurs. Chronic OxS leads to several pathologies. In the vascular system, ROS is produced by the vascular smooth muscle cells (VSMCs), endothelial cells (EC), and adventitial cells, among others. The endothelium regulates the vascular homeostatic system, as it is the barrier that separates blood and tissue. However, when the antioxidant defense system does not remove the excess ROS, it can cause endothelial dysfunction. This perturbation of the homeostatic functioning of the vascular EC leads to pathologies such as tissue ischemia and atherothrombosis. ROS is also involved in other pathophysiological processes such as hypertension, inflammation, and vascular remodeling, which leads to vascular pathologies, including atherosclerosis, arterial hypertension, and cardiovascular diseases (CVDs). Moreover, ROS-generating systems also facilitate the development of diabetes mellitus, obesity, and hypercholesterolemia, which increases the risk of developing vascular pathologies.

1.1 | ROS in general

Reactive species are molecules interacting with various biomolecules, including nucleic acids, lipids, and proteins, and generating electron-deficient species, leading to cell and tissue damages. Different endogenous metabolic and biochemical reactions and exogenous sources, such as ionizing radiation, generate these reactive species. The term “reactive oxygen species” refers to oxygen metabolites, such as superoxide anion radical (O$_2^-$), singlet oxygen ($^1$O$_2$), hydroxyl radical (OH$^-$), and perhydroxyl radical (HO$_2^*$), which are yielded by the reduction of the oxygen molecule (O$_2$) with two uncoupled electrons. Furthermore, ROS with an unpaired electron are free radicals; hence, they are also named oxygen radicals or oxygen-free radicals, and free radicals are chemical species that are capable of independent existence with one or more unpaired electron. The unpaired electron transforms the chemical reactivity of the molecule, leading to its increased reactivity compared with the non-radical form of the molecule. Thus, free-radical forms of ROS can remove electrons from other molecules to gain stability and by that causes new free radical formation, initiating a chain reaction cascade, which consequently impairs the cell/tissue functioning. In addition, the term ROS cover all oxygen-containing reactive species, namely, alkoxyl radical (LO$^*$), peroxyl radical (LOO$^*$), lipid hydroperoxide (LOOH), peroxy nitrite anion (ONOO$^-$), hypochlorous acid (HOCl), and ozone (O$_3$), from which some are without unpaired electrons (hydrogen peroxide (H$_2$O$_2$), ONOO$^-$, HOCl, and O$_3$), and as such, they are not free radicals.

In biological systems, ROS produced by cellular metabolism exert both deleterious, cytotoxic effects, as well as beneficial effects such as antimicrobial activity, metabolic pathways regulation, cell signaling, and redox signaling. Redox signaling represents pathways in which ROS or other reactive species serve as messengers to induce cellular responses via redox reactions, implicated in many different physiological and pathological processes in the organism. Thus, ROS can provoke redox modulation of protein kinase cascades and transcription factors leading to different cellular responses, such as cell proliferation and differentiation, altered expression, or synthesis of cytokine and/or adhesion molecules.

Owing to the mostly deleterious nature of ROS, mammals, including humans, have developed a robust antioxidant protection system through the action of enzymes such as Cu-Zn superoxide dismutase (Cu-Zn SOD), catalase, glutathione peroxidase, glutathione reductase, and glutathione-S-transferase. Moreover, several diet compounds, particularly from fruits and vegetables, also exhibit antioxidant activities. An imbalance between ROS generation and removal rate leads to OxS, and chronic OxS leads to different pathologies, including the vascular pathophysiology.

1.2 | Vascular physiology in general

The vascular system is finely synchronized to adjust the blood flow to the metabolic requirements of the body and is made up of a heart and a closed network of vessels (arteries, veins, and capillaries) that supply oxygen and nutrients to every tissue to maintain cellular homeostasis. Endothelium lines the interior surface of blood vessels—a single layer of homogenous EC layer being in connection with blood and lymph from the circulation and represents a surface (blood/endothelium interface) with roughly 300–1,000 m$^2$, whereas the mass is approximately 110 g.$^{18,19}$ VSMC surround the endothelium, establishing the outer layer of arteries. The fibroelastic connective layer and internal elastic lamina located below endothelium provide flexibility and stability for EC. Perivascular cells (periocytes) also surround the EC—multipotential stem cells with the possibility to differentiate into different types of cells among other VSMC, fibroblasts, osteoblasts, connective tissue cells, and adipocytes, providing the EC and VSMC with a stable microenvironment and contractile ability.

EC have a vital function in tissue homeostasis by the regulation of solute and macromolecule transport through the vessels. A glycocalyx layer on the EC surface provides a locally charged barrier to cell and protein movement from the blood through endothelium under physiological conditions.
endothelium also regulates and maintains vascular tone through interaction with the peripheral nervous system and by synthesizing and releasing vasodilatory factors such as endothelin-1 (ET-1), thromboxane, endothelium-derived hyperpolarizing factor, nitric oxide (NO), and prostacyclin.22 Another endothelium function is hemostasis regulation. That is, the endothelium synthesizes compounds, which maintain blood fluidity and are involved in the formation of nonthrombogenic surface and coagulation processes. EC are exposed to lipids (present in the circulation and accumulating in the subendothelial regions) and are also involved in immunological and inflammatory processes, which are associated with atherosclerosis and occlusive vascular disorders.23

Furthermore, the endothelium is responsible for the reaction to pathophysiological conditions such as infection or trauma of the neighboring tissues, vessel remodeling, and growth,24–26 therefore having significant diagnostic and therapeutic potential. EC is capable of synthesizing most of the proteins that constitute the basal lamina and enzymes involved in extracellular matrix remodeling such as matrix metalloproteinase (MMP), which is vital for the blood vessel plasticity and angiogenesis.27 Thus, endothelium represents an essential and dynamic endocrine organ due to its different functions as alluded to above.

The fibrinolytic system is a system that restores a blood vessel when the blood clot is not needed, and it includes an inactive proenzyme, the plasminogen, and an active form, plasmin that is responsible for fibrin degradation. The activity of plasminogen activators (PA) such as tissue-type PA (t-PA) and urokinase-type PA (u-PA) regulates the fibrinolytic potential of the vasculature.28 Activation of the EC and the proinflammatory and procoagulant response lead to the synthesis and release of u-PA.29,30 The constitutively produced protein of EC, the PA inhibitor type I (PAI-1), suppresses t-thesis and release of u-PA.29,30 The constitutively produced proinflammatory and procoagulant response lead to the synthesis and release of u-PA.29,30 The constitutively produced protein of EC, the PA inhibitor type I (PAI-1), suppresses t-thesis and release of u-PA.29,30 The constitutively produced protein of EC, the PA inhibitor type I (PAI-1), suppresses t-thesis and release of u-PA.29,30 The constitutively produced protein of EC, the PA inhibitor type I (PAI-1), suppresses t-thesis and release of u-PA.29,30 The constitutively produced protein of EC, the PA inhibitor type I (PAI-1), suppresses t-thesis and release of u-PA.29,30 The constitutively produced protein of EC, the PA inhibitor type I (PAI-1), suppresses t-thesis and release of u-PA.29,30 The constitutively produced protein of EC, the PA inhibitor type I (PAI-1), suppresses t-thesis and release of u-PA.29,30 The constitutively produced protein of EC, the PA inhibitor type I (PAI-1), suppresses t-thesis and release of u-PA.29,30 The constitutively produced protein of EC, the PA inhibitor type I (PAI-1), suppresses t-thesis and release of u-PA.29,30

Furthermore, the inhibition of the tissue factor-FVIIa (TF-FVIIa) complex occurs by its interaction with a specific polypeptide, the tissue factor pathway inhibitor (TFPI), and formation of a stable quaternary complex TFPI-TF-FVIIa-FXa.34 Thus, EC prevent blood clotting via a mechanism that involves the heparin-like molecule thrombomodulin, together with NO and prostacyclin. When an endothelial injury occurs, EC stop the secretion of coagulation and aggregation factors, and synthesize and secrete a large multimeric protein called the von Willebrand factor, which initiates the hemostasis maintenance after injury.35 In addition, EC produces the lipid-mediator platelet-activating factor, which activates platelets and their attachment to EC.36 VSMC represent one of the most frequent types of cells in arteries. VSMC are also essential for the homeostasis of the vasculature, as well as for the vasculature contractions and relaxations, which are responsible for the blood vessel luminal diameter alterations to maintain blood pressure within the normal range. VSMC contractility is controlled regularly by exchanging two different phenotypes.37 Different states of VSMC are noted among both the VSMC of the same and various blood vessels. The mature, differentiated VSMC are contractile, and their phenotype is elongated and spindle-shaped, and these VSMC display low rates of migration and proliferation and express increased levels of proteins that are important for contractility. VSMC shuttle to a dedifferentiated synthetic phenotype with rhomboid shape in certain physiological conditions, including pregnancy or exercise, and after injury of the vasculature, which is vital during vessel remodeling.38 Dedifferentiated VSMC are exceptionally proliferative and migratory and synthesizes extracellular matrix proteins, like elastin and collagen.39 Based on all these properties, VSMC are capable of regulating the vessel diameter in short terms and in long terms VSMC are responsible for adaptation by structural remodeling through changing the number of cells and the constitution of connective tissue. The VSMC marker proteins that are most significant in defining VSMC phenotypes include cellular retinol binding protein-1, smooth muscle myosin heavy chain (SM-MHC), α-smooth muscle actin, SMemb/nonmuscle MHC-B, and smoothelin A and B.38 A few of these proteins are structural components of the contractile apparatus or act as the contraction regulators. Generally, the loss of proteins essential to the contractile phenotype indicates the synthetic phenotype. The expression of the two marker proteins, SM-MHC, and smoothelin, characterizes a mature contractile VSMC phenotype.40

2 | EFFECTS OF ROS

The human body uses a cellular antioxidant defense system to neutralize free radicals and, consequently, OxS. In OxS, ROS are involved directly or indirectly in the
macromolecules deterioration, along with oxidative deterioration of nucleic acids, proteins, and lipids. However, ample evidence suggests that ROS directly activate OxS-responsive pathways regulating different cellular processes, additionally leading to the progression of diseases. OxS is associated with carcinogenesis, neurodegeneration, atherosclerosis, diabetes, and aging. ROS are also critical physiological modulators of the redox state signaling molecules. ROS changes the function of the protein by the mechanism that includes the modifications of cysteine (Cys) residues, which are redox-reactive. Cys residue oxidation promotes the formation of reactive sulfenic acid (─SOH) that can interact with nearby Cys-forming disulfide (─S─S─) bonds or endure additional oxidation to sulfenic (─SO₂H) or sulfonic (─SO₃H) acid. These modifications (except sulfonic acid and to a lower extent sulfenic acid) reverse specific reducing systems including peroxiredoxin and thioredoxin, suggesting that these modifications are involved in redox sensing and signaling and regulation of protein structure/function. Numerous studies show that ROS influence many different signaling pathways involving molecules, such as tyrosine and Rho kinases, mitogen-activated protein (MAP) kinases, transcription factors (HIF-1, nuclear factor-kappaB [NF-κB], and activator protein-1 [AP-1]), as well as protein tyrosine phosphatases (PTPs) involved in cardiovascular, neural, and renal cell function. ROS elevates the concentration of intracellular free Ca²⁺ ([Ca²⁺]ᵢ) by the activation of ion channels, and ROS upregulates the expression of proinflammatory and proto-oncogene genes (Figure 1).  

3 | REDOX SIGNALING IN THE VASCULAR PATHOPHYSIOLOGY

In vascular tissue, diverse systems generating ROS interrelate to establish a combined redox modulation. Nonetheless, the majority of tissue damage and pathology is a result of excessive ROS production, which leads to inflammation in the vascular tissues, while excessively low levels of ROS interrupt the oxidant physiological role in vasodilation and cellular growth. Furthermore, it has been suggested that “intermediate” ROS levels could facilitate the physiological response in the vasculature, while chronically elevated ROS level characteristic for OxS could be associated with CVD. Hence, ROS participate in the pathophysiology of the vascular disease, but also regulate vascular function in healthy vessels (Table 1). In addition, ROS is part of an adaptive response in vascular diseases. In Table 2, we summarized some of the effects of ROS on vascular physiology in animal and human studies. These distinctive roles of ROS may be a consequence of the different physicochemical properties of ROS. For example, H₂O₂ biological half-life is expanded compared with the half-life of O₂⁻ and OH⁻ and can diffuse through lipid membranes, and the charge of the O₂⁻ molecule prevents it from crossing the cell membranes except for the possibility to cross the membrane through ion channels. Besides, reductive stress (RS) is another deleterious factor that disturbs the redox state and promotes vascular pathophysiology. Furthermore, RS increases s-glutathionylation of proteins, and that may be involved in

**FIGURE 1**  Effects of ROS in physiological and pathophysiological conditions
uncoupling of eNOS that elevates \( \text{O}_2^- \) production and induces OxS.\textsuperscript{103–106}

### 3.1 Xanthine and NAD(P)H oxidase as the culprit of ROS in vascular pathophysiology

The most prominent origins of ROS in the vascular tissue are xanthine oxidase (XO) and NAD(P)H oxidase. NAD(P)

\[ \text{H}_2\text{O}_2 \]

- From \( \bullet \text{O}_2 \) by SOD
- Directly produced by:
  - Glucose oxidase
  - Xanthine oxidase
  - \(-\text{NADPH oxidase 4 isoform}\)

\[ \bullet \text{OH} \]

- Produced in Haber–Weiss reaction from \( \bullet \text{O}_2 \) and \( \text{H}_2\text{O}_2 \)
- From reactions with hypochlorous acid

\[ \bullet \text{ONOO}^- \]

- Produced in reaction of NO and \( \bullet \text{O}_2 \)

\[ \bullet \text{OH} \]

- Produced in Haber–Weiss reaction from \( \bullet \text{O}_2 \) and \( \text{H}_2\text{O}_2 \)
- From reactions with hypochlorous acid

\[ \bullet \text{ONOO}^- \]

- Produced in reaction of NO and \( \bullet \text{O}_2 \)

\[ \text{O}_2^- \]

- The electron transport chain of mitochondria
- Monoxygenase
- NADPH oxidase
- Xanthine oxidase
- Lipooxygenase
- eNOS uncoupling

\[ \text{H}_2\text{O}_2 \]

- From \( \bullet \text{O}_2 \) by SOD
- Directly produced by:
  - Glucose oxidase
  - Xanthine oxidase
  - \(-\text{NADPH oxidase 4 isoform}\)

\[ \bullet \text{OH} \]

- Produced in Haber–Weiss reaction from \( \bullet \text{O}_2 \) and \( \text{H}_2\text{O}_2 \)
- From reactions with hypochlorous acid

\[ \bullet \text{ONOO}^- \]

- Produced in reaction of NO and \( \bullet \text{O}_2 \)

\[ \text{O}_2^- \]

- The electron transport chain of mitochondria
- Monoxygenase
- NADPH oxidase
- Xanthine oxidase
- Lipooxygenase
- eNOS uncoupling

\[ \text{H}_2\text{O}_2 \]

- From \( \bullet \text{O}_2 \) by SOD
- Directly produced by:
  - Glucose oxidase
  - Xanthine oxidase
  - \(-\text{NADPH oxidase 4 isoform}\)

\[ \bullet \text{OH} \]

- Produced in Haber–Weiss reaction from \( \bullet \text{O}_2 \) and \( \text{H}_2\text{O}_2 \)
- From reactions with hypochlorous acid

\[ \bullet \text{ONOO}^- \]

- Produced in reaction of NO and \( \bullet \text{O}_2 \)

\[ \text{O}_2^- \]

- The electron transport chain of mitochondria
- Monoxygenase
- NADPH oxidase
- Xanthine oxidase
- Lipooxygenase
- eNOS uncoupling

\[ \text{H}_2\text{O}_2 \]

- From \( \bullet \text{O}_2 \) by SOD
- Directly produced by:
  - Glucose oxidase
  - Xanthine oxidase
  - \(-\text{NADPH oxidase 4 isoform}\)

\[ \bullet \text{OH} \]

- Produced in Haber–Weiss reaction from \( \bullet \text{O}_2 \) and \( \text{H}_2\text{O}_2 \)
- From reactions with hypochlorous acid

\[ \bullet \text{ONOO}^- \]

- Produced in reaction of NO and \( \bullet \text{O}_2 \)

\[ \text{O}_2^- \]

- The electron transport chain of mitochondria
- Monoxygenase
- NADPH oxidase
- Xanthine oxidase
- Lipooxygenase
- eNOS uncoupling

\[ \text{H}_2\text{O}_2 \]

- From \( \bullet \text{O}_2 \) by SOD
- Directly produced by:
  - Glucose oxidase
  - Xanthine oxidase
  - \(-\text{NADPH oxidase 4 isoform}\)

\[ \bullet \text{OH} \]

- Produced in Haber–Weiss reaction from \( \bullet \text{O}_2 \) and \( \text{H}_2\text{O}_2 \)
- From reactions with hypochlorous acid

\[ \bullet \text{ONOO}^- \]

- Produced in reaction of NO and \( \bullet \text{O}_2 \)

\[ \text{O}_2^- \]

- The electron transport chain of mitochondria
- Monoxygenase
- NADPH oxidase
- Xanthine oxidase
- Lipooxygenase
- eNOS uncoupling

\[ \text{H}_2\text{O}_2 \]

- From \( \bullet \text{O}_2 \) by SOD
- Directly produced by:
  - Glucose oxidase
  - Xanthine oxidase
  - \(-\text{NADPH oxidase 4 isoform}\)

\[ \bullet \text{OH} \]

- Produced in Haber–Weiss reaction from \( \bullet \text{O}_2 \) and \( \text{H}_2\text{O}_2 \)
- From reactions with hypochlorous acid

\[ \bullet \text{ONOO}^- \]

- Produced in reaction of NO and \( \bullet \text{O}_2 \)

\[ \text{O}_2^- \]

- The electron transport chain of mitochondria
- Monoxygenase
- NADPH oxidase
- Xanthine oxidase
- Lipooxygenase
- eNOS uncoupling

\[ \text{H}_2\text{O}_2 \]

- From \( \bullet \text{O}_2 \) by SOD
- Directly produced by:
  - Glucose oxidase
  - Xanthine oxidase
  - \(-\text{NADPH oxidase 4 isoform}\)

\[ \bullet \text{OH} \]

- Produced in Haber–Weiss reaction from \( \bullet \text{O}_2 \) and \( \text{H}_2\text{O}_2 \)
- From reactions with hypochlorous acid

\[ \bullet \text{ONOO}^- \]

- Produced in reaction of NO and \( \bullet \text{O}_2 \)

\[ \text{O}_2^- \]

- The electron transport chain of mitochondria
- Monoxygenase
- NADPH oxidase
- Xanthine oxidase
- Lipooxygenase
- eNOS uncoupling

\[ \text{H}_2\text{O}_2 \]

- From \( \bullet \text{O}_2 \) by SOD
- Directly produced by:
  - Glucose oxidase
  - Xanthine oxidase
  - \(-\text{NADPH oxidase 4 isoform}\)

\[ \bullet \text{OH} \]

- Produced in Haber–Weiss reaction from \( \bullet \text{O}_2 \) and \( \text{H}_2\text{O}_2 \)
- From reactions with hypochlorous acid

\[ \bullet \text{ONOO}^- \]

- Produced in reaction of NO and \( \bullet \text{O}_2 \)

\[ \text{O}_2^- \]

- The electron transport chain of mitochondria
- Monoxygenase
- NADPH oxidase
- Xanthine oxidase
- Lipooxygenase
- eNOS uncoupling

\[ \text{H}_2\text{O}_2 \]

- From \( \bullet \text{O}_2 \) by SOD
- Directly produced by:
  - Glucose oxidase
  - Xanthine oxidase
  - \(-\text{NADPH oxidase 4 isoform}\)

\[ \bullet \text{OH} \]

- Produced in Haber–Weiss reaction from \( \bullet \text{O}_2 \) and \( \text{H}_2\text{O}_2 \)
- From reactions with hypochlorous acid

\[ \bullet \text{ONOO}^- \]

- Produced in reaction of NO and \( \bullet \text{O}_2 \)

\[ \text{O}_2^- \]
**TABLE 2**  The effects of ROS on vascular physiology- animal and human studies

| Effects of ROS | Condition and/or treatment | Species | Ref. |
|----------------|-----------------------------|---------|------|
| • Endothelial dysfunction | ↓ OxS | Ang II-induced vascular dysfunction | dTGR | 88 |
| | ↑ XO activity | | SDR | |
| • ↓ Arteriolar tone | ↑ XO activity | | SHR | 89 |
| • Correct hypertrophy of renal and cardiac tissue | ↑ XO activity | Allopurinol | SHR | 90, 91 |
| | Sodium restriction | | DSS rats | |
| • ↑ Systolic blood pressure | ↑ O$_2^-$ | Irbesartan | SHR | 92 |
| • Endothelial dysfunction | ↓ p22$^{phox}$ mRNA | | WKY | |
| • Vascular hypertrophy | | | |
| • Atherosclerosis | ↑ ROS | Ang II-mediated MAP kinase activation | Rat VSMC | 93 |
| • ↓ Systolic blood pressure | ↑ O$_2^-$ | Ang II-induced hypertension | | 94 |
| • Stimulate vascular smooth muscle cell growth | ↑ H$_2$O$_2$ | Naphthoquinolinedione | LY83583 | 95 |
| | ↑ O$_2^-$ | | |
| • ↓ Expression of proinflammatory molecules | ↑ O$_2^-$ | Angiotensin receptor inhibition | Hypertensive | 58 |
| | | gp$^{p22phox}$ NAD(P)H oxidase inhibition | DSS rat | |
| • ↓ Vascular superoxide production | ↑ superoxide production | ETA receptor inhibition | DOCA-salt hypertensive mice and rats | 96, 97 |
| | ↑ ET-1 | | |
| • Attenuated blood pressure elevation | ↑ O$_2^-$ | Ang II–induced hypertension | Mice/ Aortic rings | 46 |
| | | Inhibited association of p47$^{phox}$ and gp91$^{phox}$ | |
| • ↑ Mean blood pressure Nox1(+/Y) | ↑ ROS | Ang II-induced hypertension | Nox1-deficient (−/−) mice | 98 |
| • ↓ Production of superoxide in Nox1(−/−) | | | |
| • Preserved endothelium-dependent relaxation in Nox1(−/−) | | | |
| • ↑ Systolic blood pressure | ↑ superoxide production | VSMC TgSMCnox1 | | 99 |
| • ↑ Aortic hypertrophy | | | |
| • Development of cardiovascular pathologies | | | |
| • No changes in blood pressure of p47$^{phox}/−/−$ deficient mice after Ang II treatment | ↑ O$_2^-$ | p47$^{phox}/−/−$ deficient mice | | 63 |
| • ↓ Aneurysm formation | ↑ ROS | NADPH oxidase inhibition | iNOS$^{−/−}$ mice | 100 |
| • ↓ NO levels | | | |
| • Dysfunction of the endothelium | - | ET-1 overexpression | C57BL/6 TG and WT mice | 101 |
| • vascular remodeling | | | |
| • ↓ NO levels | ↑ O$_2^-$ production | PMA stimulation | Hypertensive and normotensive patients | 102 |
| • ↑ Oxidized/reduced glutathione ratio | ↑ ROS | - | Hypertensive and normotensive patients | 53 |
| • ↓ Activity of superoxide dismutase, catalase, and glutathione peroxidase | | | |
| • Development of cardiovascular complications | | | |

**Abbreviations:** ↑, increased; ↓, decreased; Ang II, angiotensin II; DOCA, salt-deoxycorticosterone acetate-salt; DSS, Dahl salt-sensitive; dTGR, double-transgenic rats; ET-1, endothelin-1; iNOS$^{−/−}$, iNOS-deficient; ONOO$^-$, peroxynitrite; OxS, oxidative stress; PMA, phorbol myristate acetate; SDR, Sprague Dawley rats; SHR, spontaneously hypertensive rats; TG, transgenic; TgSMCnox1, transgenic mice overexpressing Nox1 in smooth muscle cells; VSMC, vascular smooth muscle cell; WKY, Wistar-Kyoto rats; WT, wild type (nontransgenic); XO, xanthine oxidase.
other hand, in spontaneously hypertensive rats (SHR), increased activity of XO was found in the microcirculation of the mesentery. The increased XO activity has also been found in the renal tissue of SHR and Dahl salt-sensitive (DSS) rats, while the discovery that allopurinol can correct the hypertrophy of renal and cardiac tissue in SHR without lowering the blood pressure implies the involvement of XO in organ damage induced by elevated blood pressure. The membrane-bound p22phox subunit is crucial for the NAD(P)H oxidase complex activation and is accompanied by an elevated production of O$_2^-$ in humans with coronary artery disease. The increased levels of OxS byproducts, together with elevated oxidative DNA damage, were found in samples obtained from patients with arterial hypertension.

The mononuclear cells isolated from the blood of patients with essential hypertension exhibited increased O$_2^-$ production after treatment with angiotensin II (Ang II) or ET-1 when compared with controls. The majority of studies investigating NAD(P)H oxidase activation in vascular cells focused on Ang II signaling, which implicates receptor tyrosine kinases, protein kinase C, c-Src, and phospholipase D. The expression/activity of NAD(P)H oxidase was found to be increased in rats with hypertension caused by Ang II treatment. A NAD(P)H oxidase inhibitor, decreasing both vascular O$_2^-$ synthesis and hypertension in mice, supports this finding. The reduced production of O$_2^-$ and the blunted effect of Ang II on the blood pressure were both found in Nox1-deficient mice.

On the other hand, the overexpression of Nox1 enhances Ang II-induced O$_2^-$ formation, VSMC hypertrophy, and hypertension in transgenic mice. Furthermore, in cytosolic NAD(P)H p47phox subunit-deficient mice, the endothelial dysfunction, O$_2^-$ production, and Ang II-induced hypertensive response were blunted. Moreover, NAD(P)H oxidase was associated with raised O$_2^-$ production in the arterial tissue of SHR.

The produced ROS from NAD(P)H oxidase can react with products of nitric oxide synthase (NOS), which may further amplify vascular function. For example, O$_2^-$ generated from NAD(P)H oxidase reacts with NO, forming peroxynitrite (ONOO$^-$), which consequently induces changes in the NOS enzyme subunits resulting in further O$_2^-$ formation and the declination of NO bioavailability, which impairs endothelium-dependent relaxation in a model of salt-induced hypertensive rats. ROS synthesized by NAD(P)H oxidase is required for iNOS expression in microvascular EC.

The membrane-bound gp91phox-containing NAD(P)H oxidase is identified as a source of excessive O$_2^-$ linked with elevated activity of the renin–angiotensin system as shown in renovascular and salt-induced hypertension models. Treatments with the angiotensin receptor blocker and with the gp91phox NAD(P)H oxidase inhibitor restrained the elevated O$_2^-$ aortic generation and the expression of the proinflammatory molecules in a model of hypertensive DSS rats. Importantly, ROS-induced injury was shown to lead to further ROS formation while proinflammatory cytokines activated the system of NAD(P)H oxidase.

Furthermore, ROS produced at one subcellular locus can initiate ROS synthesis in another locus by signal transmission. For example, mitochondria-derived ROS production activates ROS formation by NAD(P)H oxidase. The NAD(P)H oxidase increased activity in pulmonary microvascular EC produces extracellular O$_2^-$ and consequently, promotes the progression of atherosclerosis.

The ET-1 also induces an increase in ROS generation by the activation of NAD(P)H oxidase pathway. ET-1 via ETA receptor activation increases O$_2^-$ production in the DOCA-salt hypertensive rat model, while the ETA receptor inhibition decreases the production of vascular superoxide. Moreover, endothelium-restricted human ET-1 overexpression was shown to cause dysfunction of the endothelium and vascular remodeling in mice through the NAD(P)H oxidase pathway. Besides, NAD(P)H oxidase pathway, dysfunction of endothelium, and vascular remodeling can be the result of an activated extracellular signal–regulated kinases (ERK) signaling pathway. Numerous studies have shown that increased level of oxLDL induces accumulation of ROS, which stimulates ERK phosphorylation, upregulates the expression of endothelial transcriptional factor AP-1 and ET-1, and, consequently, promotes the progression of atherosclerosis.

Activation of NAD(P)H oxidase is also involved in the pathogenesis of abdominal aortic aneurysm. That is, samples obtained from subjects suffering from aneurysms of the abdominal aorta exhibit overexpressed NADPH oxidase and raised level of O$_2^-$ in the endothelium and within the aortic wall. ROS synthesized by the NAD(P)H oxidase activity facilitate the inflammatory process in the aortic endothelium and stimulate the extracellular matrix impairment through...
the MMP-2 activation and apoptosis of VSMC. A murine aneurysm model was used to show that inhibition of ROS mitigates the formation of the aneurysm.\textsuperscript{100} Also, the cyclic stretch of VSMC stimulates the expression of MMP-2. This response is blunted in murine cells deficient in the p47\textsuperscript{phox} subunit of NAD(P)H oxidase, thus implying the function of ROS generated by the NAD(P)H oxidase in MMP-2 signaling in VSMC.\textsuperscript{122} Moreover, Ang II induces MMP-2 via the p47\textsuperscript{phox} subunit.\textsuperscript{123} Also, ROS generated by macrophage-derived foam cells modifies the activity of MMP-2 and MMP-9 in vitro.\textsuperscript{124}

Various growth factors (such as PDGF and transforming growth factor \(\beta\)) and hormones are involved in the modulation of NAD(P)H oxidase activity/expression, while ROS regulates the activity of many signaling enzymes (tyrosine and MAP kinases, PTPs) in the vasculature.\textsuperscript{3} Redox signaling also mediates the activity of transcription factors in the vascular cells. In addition, the laminar flow and the shear stress influence the ROS activity in both physiological and pathophysiological settings.

### 3.2 The effects of ROS on tyrosine and MAP kinases, and PTPs in vascular pathophysiology

ROS regulates the tyrosine kinases (receptor and nonreceptor forms) in the vasculature. Receptor tyrosine kinases, PDGF receptor beta (PDGFR-\(\beta\)), and the epidermal growth factor receptor (EGFR) require ligand-stimulated signal transduction. It appears that H\(_2\)O\(_2\) generation is mandatory for signal transmission through PDGFR-\(\beta\).\textsuperscript{125,126} Furthermore, Ang II stimulates EGFR and PDGFR-\(\beta\) through transactivation. The nonreceptor tyrosine kinase Src also contributes to the H\(_2\)O\(_2\)-dependent Ang II-stimulated EGFR transactivation.\textsuperscript{127} Activation of tyrosine kinases regulates NAD(P)H oxidase, which additionally amplifies ROS production in the vascular tissue. The transactivation of EGFR and PDGFR-\(\beta\) stimulates MAP kinases in VSMC.\textsuperscript{128}

PDG and Ang II activate MAP kinases in the vascular tissue.\textsuperscript{129} H\(_2\)O\(_2\) and O\(_2^-\) activate MAP kinases in VSMC.\textsuperscript{95} H\(_2\)O\(_2\) stimulates p38 MAP kinase, required for redox-sensitive signal transduction initiated by Ang II in VSMC.\textsuperscript{130} ROS implicated in MAP kinase activation induced by Ang II has also been derived from NAD(P)H oxidase in VSMC.\textsuperscript{93}

Protein tyrosine phosphorylation is also affected by ROS. Protein tyrosine kinases (PTK) and PTPs regulate tyrosine phosphorylation. The complex of PTP enzymes dephosphorylates PTK substrate proteins and counteracts PTK activity. Both receptor and nonreceptor PTPs are susceptible to O\(_2^-\) and H\(_2\)O\(_2\). Exposure of cells to ROS inactivates PTP through oxidation of Cys residue in its structure and increases protein phosphorylation.\textsuperscript{131} However, this process is reversible, and PTPs is present in two states, either with a reduced or with oxidized Cys. Ang II may influence the oxidation of PTP-activated NAD(P)H oxidase and O\(_2^-\) generation.\textsuperscript{132,133} Also, Ang II stimulates the expression of the vascular cell adhesion molecule-1 via NF-\(\kappa\)B activation through ROS signaling.\textsuperscript{134}

### 3.3 ROS-induced activation of transcription factors in vascular pathophysiology

The activation of ROS by NF-\(\kappa\)B occurs through the activation of inhibitory \(\kappa\)B kinases. The NF-\(\kappa\)B signaling modulates the expression of genes involved in inflammation and stimulates the ROS generation. In diabetic mice, the activation of NF-\(\kappa\)B increased the generation of the proinflammatory cytokine, the tumor necrosis factor-alpha, which in turn elevated O\(_2^-\) production by NAD(P)H oxidase.\textsuperscript{135} Ang-II stimulated endothelial ROS generation through the stimulation of NF-\(\kappa\)B signaling pathway in DSS rats.\textsuperscript{136} One of the sources of ROS (O\(_2^-\) and H\(_2\)O\(_2\)) generated through NF-\(\kappa\)B signaling is NAD(P)H oxidase. The NF-\(\kappa\)B cis-acting elements regulate the promoter of p22\textsuperscript{phox}NAD(P)H oxidase gene in human aortic smooth muscle cells.\textsuperscript{137} The findings that revealed that NF-\(\kappa\)B enters the mitochondria of the obese mouse with diabetes and increases mitochondrial O\(_2^-\) suggest the non-transcriptional role of NF-\(\kappa\)B in ROS production.\textsuperscript{138} Since NF-\(\kappa\)B activity leads to elevated ROS production, while ROS activates NF-\(\kappa\)B, the ROS generated by NAD(P)H oxidase will upregulate NF-\(\kappa\)B, initiating a positive feedback mechanism for ROS generation.\textsuperscript{108}

### 4 HEMODYNAMICS AND REDOX SIGNALING

Redox signaling likely also influences the mechanical forces acting on the vascular wall. That is, elevated intraluminal flow stimulates the generation of O\(_2^-\) and H\(_2\)O\(_2\) in intact blood vessels. In VSMCs, shear stress was demonstrated to induce ROS generation.\textsuperscript{139} The ROS activity in cultured EC during oscillatory shear stress is derived from the activation of XO. The attenuation of O\(_2^-\) production in the vasculature affected by oscillatory shear stress is derived from the activation of XO. The attenuation of O\(_2^-\) production in the vasculature affected by oscillatory shear stress was found in cells lacking NAD(P)H oxidase activity, or by application of oxyurinol, a specific blocker of XO.\textsuperscript{107} However, the exact mechanism is still undetermined and may implicate NAD(P)H, and XO and/or mitochondrial enzymes.\textsuperscript{132} Laminar shear upregulates the expression of the extracellular SOD and cytosolic copper and zinc SOD in human aortic EC, and may regulate protective vascular response.\textsuperscript{140} Finally, ROS, particularly O\(_2^-\) and H\(_2\)O\(_2\), can diminish the efficacy of the antioxidant system, leading to the promotion of OxS. These signaling molecules play a significant role in the pathophysiology of the vasculature.
5 | DEVELOPING LEADS TO EXTEND OUR UNDERSTANDING OF REDOX CONTROL OF VASCULAR BIOLOGY

Data-mining and text-mining techniques have been used to explore the information contained in published biomedical literature. Advancements in these techniques have led to the development of several topic-specific knowledgebases (KB),141–159 including the first topic-specific KB for redox control of vascular systems, named DES-RedoxVasc.160

DES-RedoxVasc was constructed using the search query: (human OR mouse OR rat OR mammal*) AND (radical* OR peroxide* OR “reductive stress” OR ROS OR “reactive oxygen species” OR RNS OR “reactive nitrogen species” OR redox OR “reduction–oxidation reaction” OR oxidative OR nitrosative OR peroxide* OR superoxide* OR detoxify* OR antioxidant* OR “polysaturated fatty acids” OR “arachidonic acid” OR “linoleic acid” OR hydperoxide* OR “hypochlorous acid” OR peroxy nitrit* flavoprot* OR xanthine oxidase* OR “cytochromes P450” OR catalase* OR sulfiredoxin* OR peroxiredoxin*) AND (“angiogenesis” OR anemia OR aneurysm* OR angio* OR arter* OR atrial OR atrioventricular OR aort* OR bradycardia OR blood OR brain OR circulati* OR clogging OR cardio* OR coronary OR edema OR heart OR ischemic OR hemo* OR hypertension OR leukemia OR leuto* OR macroangiopathy OR microangiopathy OR neovascularization OR occlusion OR pericardi* OR sepsis OR “sickle cell” OR tachycardia OR tachyarrhythmia OR thromb* OR vaso OR vein* OR ventricular OR vascular* OR vessel*) to retrieve all literature specifically focused on research related to redox effects from 233 PubMed Central documents (based on the article abstracts) and PubMed Central documents (based on the complete text in the article) linked to redox processes in the cardiovascular system. Users can easily explore the analyzed documents in DES-RedoxVasc through links between various concepts from 28 topic-specific dictionaries such as pathways, diseases, genes/proteins, miRNAs, toxins, drugs, biological processes, molecular functions, and so on. DES-RedoxVasc can be used to search for hypotheses and potentially new knowledge in vascular biology. A published example in 160 shows that the semantic similarity tool in this KB linked ZFAS1 (long noncoding RNA) and miR-27b, even though there is no literature linking the functioning of miR-27b and ZFAS1. Nonetheless, miR-27b and ZFAS1 are linked to different vascular pathologies, and the DIANA tool, LncBase Predicted v.2,161 predicts that ZFAS1 binds hsa-miR-27b-3p, which supports the possibility that the link suggested by DES-RedoxVasc may be correct. The possible role of ZFAS1 in the fine tuning of levels of miR-27B, a microRNA that is known to be responsive to OxS, has not been explored.160 As a consequence, we used DES-RedoxVasc to develop additional case studies.

Case Study 1: Here, we characterize the biological functions of VSMC relative to chemical substances in the literature in connection with both VSMC and gene ontology biological functions that were associated with VSMC. As such, Figure 2 gives an overview of substances that are vital for homeostasis or can disturb the proper functioning of VMSC.

The following redox-related molecules discussed in this manuscript were retrieved: “oxygen radical,” “superoxide,” and “hydrogen peroxide.” However, DES-RedoxVasc points out additional molecules that should be explored (via https://www.cbrc.kaust.edu.sa/des-rv/) in this context. For instance, it would be interesting to look at the relationship between “H2O2” and “Ang II,” as Ang II and other chemotactic factors are dependent on H2O2 for their release.162 It is therefore of interest knowing which GO terms are linked to both H2O2 and Ang II. In the DES-RedoxVasc KB, they are linked to vasodilation, vasoconstriction, macrophage activation, as well as VSMC that were the starting point of this exploration.

Case Study 2: Studies have demonstrated that both dietary PUFA and fish oils exhibit a protective role in CVD.163–166 PUFAs provide several benefits including modulating lipid metabolism, reducing the production of inflammatory cytokine, and facilitating improvements in vascular EC function.167 PUFAs also transiently increase the levels of ROS that activate the OxS-response transcription factor NFE2L2/NRF2 (nuclear factor, erythroid derived 2, like 2) in pigment epithelial cells from the human retina,168 which transcribe several antioxidant genes. PUFAs were also shown to modulate noncoding RNAs169,170 that may be the mechanism used to mediate the chemoprotective and anticongenic properties of PUFAs. Thus, we here also used DES-RedoxVasc to explore the microRNAs linked to vascular ECs, OxS response, and n-3 polysaturated fatty acids (PUFA) (see Figure 3). We start this exploration by clicking the “Enriched Concepts” link in DES-RedoxVasc. On this page, we used the search bar to filter the concept “vascular endothelial cell,” and then used this concept right-click menu to generate a network (see Figure 3). On the “Network” page, we selected four dictionaries including “HFO Ontology (Biportal) Heart Failure Ontology,” “Pathways (KEGG, Reactome, UniPathway, Panter),” and “Human microRNAs” dictionaries. Then, the “vascular endothelial cell” node was highlighted to expand the associated concepts with links from the selected dictionaries. Then, we only selected the “Human microRNAs” dictionary (as microRNAs linked to vascular ECs, OxS response, and PUFAs are the focus of this case study), and highlighted the “Oxidative stress response” node to expand/link the
associated concepts from the “Human microRNAs” dictionary. We repeated this step for other nodes including the “Polyunsaturated Fatty Acids,” “MIR3178,” and “MIR937.” All additional nodes with two or more edges (“MIR34A,” “MIR20B,” and “MIR7A2”), generated in step 3, were also expanded/linked with their associated concepts in the “Human microRNAs” dictionary. We then pruned the nodes using the connectivity threshold of 2 (see Figure 3).

Several of the noncoding RNAs (“MIR15B” [miR-15b], “MIR16” [miR-16], “MIR17” [miR-17], and “MIR20B” [miR-20b]) retrieved by DES-RedoxVasc are modulated by PUFAs. That is, three different PUFA-treated glioblastoma cell lines consistently exhibited an increase in the levels of miR-20b, and decreased levels of microRNA (miR-16 and miR-17) that induces apoptosis-specific expression changes. In addition, the level of miR-15b increases in rats injected with the colon carcinogen and azoxymethane, and fed by fish oil/n-3 PUFA rich diets.

This report by is interesting as the generation of mitochondrial ROS is promoted by miR-15b, as well as mitochondrial dysfunction, through the inhibition of SIRT4 (exclusively localized in mitochondria). SIRT4 is also associated with photoaged skin and stress-induced cellular senescence, which linked senescence-associated mitochondrial dysfunction to both miR-15b and SIRT4. Moreover, miR-20b upregulated by PUFAs directly targets AKT3, and AKT3 silencing decreases the levels of VEGF. Specifically, in primary ECs, VEGF stimulation and the downstream mitochondrial biogenesis process required AKT3, and the blockade of AKT3 also reduces PGC-1α-dependent gene expression. This suggests that even though mitochondrial biogenesis is tightly interlinked to antioxidant...
systems, both miR-15b and miR-20b prevent mitochondrial functioning under unregulated OxS conditions. This decrease in mitochondrial biogenesis substantially decreases dysfunctional mitochondria produced by excessive ROS, which can be viewed as a quality-control process.

Figure 3 further shows that both the “MIR20B” and “VASCULAR ENDOTHELIAL CELL” nodes are further linked to two additional microRNAs, “MIR3178” (miR-3,178) and “MIR937” (miR-937), which suggest that they may function in the same or a closely linked mechanism. For now, we know that the levels of miR-20b, miR-937, and miR-3,178 are upregulated in a human vascular EC line (EAhy926) infected with the DENV-2 (TR1751 strain),176 which may be a consequence of a mechanism counteracting the DENV infection-induced OxS.177

6 | CONCLUDING REMARKS

Endothelial ROS production has a prominent role in regulating the vascular redox homeostatic mechanisms in the vascular system. By understanding the ROS/RNS removal processes, we may influence the overall perturbing homeostatic functioning of the vascular endothelial system and the underlining consequence of a disbalance portraying as OxS in which it elevates inflammation and vascular remodeling, activating the events for CVD.

The most prevailing players in vascular ROS pathology are XO and NAD(P)H oxidase, with links to various models of heart failure, ischemia injury, and DNA damage in patients with arterial hypertension, and so on. Interestingly, NAD(P)H was found to be in an ROS MMP-2 signaling pathway in VSMC, suggesting some interwoven pathways of redox signaling, PTK and phosphatase activation, growth factors, vasoactive hormones, and transcription factors. To broaden our understanding of the redox control of the vascular endothelial system, we used text mining and data mining techniques to explore new intricacies of information embedded in the biomedical literature that we may not be aware of at first glance. By retrieving redox relating molecules from the DES-RedoxVasc, we established new links and relationships between different components, such as with hydrogen peroxide and with Ang II. The results also suggest an overlapping interplay of processes that connect mitochondrial biogenesis and antioxidant systems with miR-3178 and miR-937. This shows that a cell expresses a quality control mechanism in the Redox homeostatic mechanisms of the vascular endothelial system. By using data mining in a review process, we have also deepened our understanding to our view the intricacies of how ROS is utilized in the vascular endothelial system redox system and also easier to see new pathways for improved treatment and more adequate prevention of cardiovascular-related diseases.
ACKNOWLEDGMENTS

This work is part of the collaboration between the Laboratory of Radiobiology and Molecular Genetics, Vinca Institute of Nuclear Sciences, University of Belgrade, Belgrade, Serbia and King Abdullah University of Science and Technology (KAUST), Computational Bioscience Research Center (CBRC), Thuwal, Saudi Arabia. This work has been supported by grants No. 173033 (E.R.I.) from the Ministry of Education, Science and Technological Development, Republic of Serbia and by the KAUST grant ORS#4129 (to E.R.I. and V.B.B.), which also supported M.O., S.Z., E.S.M., and V.P.B. V.B.B. has been supported by the King Abdullah University of Science and Technology Fund (BAS/1/1606-01-01), and V.B.B. and M.E. by KAUST Office of Sponsored Research (OSR) Awards No. FCC/1/1976-24-01 and FCC/1/1976-17-01. M.O., S.Z., E.S.M, A.T., J.S., and V.P.B. have been supported by the grants No. 173033 (E.R.I.) and No. 173034 from the Ministry of Education, Science and Technological Development, Republic of Serbia.

CONFLICT OF INTEREST

The authors declare no potential conflict of interest.

ORCID

Milan Obradovic https://orcid.org/0000-0002-4769-2652

REFERENCES

1. Di Meo S, Reed TT, Venditti P, Victor VM. Role of ROS and RNS sources in physiological and pathological conditions. Oxid Med Cell Longev. 2016;2016:1245049.
2. Zinkevich NS, Gutterman DD. ROS-induced ROS release in vascular biology: Redox-redox signaling. Am J Physiol Heart Circ Physiol. 2011;301:H647–H653.
3. Paravicini TM, Touyz RM. Redox signaling in hypertension. Cardiovasc Res. 2006;71:247–258.
4. Incalza MA, D’Oria R, Natalicchio A, Perrini S, Lavioila L, et al. Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. Vascul Pharmacol. 2018;100:1–19.
5. Khazaie M, Moien-Afshari F, Laher I. Vascular endothelial function in health and diseases. Pathophysiology. 2008;15:49–67.
6. Al Ghoulieh I, Khoo NK, Knaus UG, Griendling KK, Touyz RM, et al. Oxidases and peroxidases in cardiovascular and lung disease: New concepts in reactive oxygen species signaling. Free Radic Biol Med. 2011;51:1271–1288.
7. Bir SC, Kolluru GK, Fang K, Kevil CG. Redox balance dynamically regulates vascular growth and remodeling. Semin Cell Dev Biol. 2012;23:745–757.
8. Tabet F, Schiffrin EL, Callera GE, et al. Redox-sensitive signaling by angiotensin II involves oxidative inactivation and blunted phosphorylation of protein tyrosine phosphatase SHP-2 in vascular smooth muscle cells from SHR. Circ Res. 2008;103:149–158.
9. Togliatto G, Lombardo G, Brizzi MF. The future challenge of reactive oxygen species (ROS) in hypertension: From bench to bed side. Int J Mol Sci. 2017;18:1–17.
10. Ahsan H, Ali A, Ali R. Oxygen free radicals and systemic autoimmunity. Clin Exp Immunol. 2003;131:398–404.
11. Halliwell B. Antioxidants in human health and disease. Annu Rev Nutr. 1996;16:33–50.
12. Li R, Jia Z, Trush MA. Defining ROS in biology and medicine. React Oxyg Species (Apex). 2016:1–9.
13. (2012) Free Radical Biomedicine: Principles, Clinical Correlations, and Methodologies. UAE, Bentham Science Publishers.
14. Phaniendra A, Jestadi DB, Periyasamy L. Free radicals: Properties, sources, targets, and their implication in various diseases. Indian J Clin Biochem. 2015;30:11–26.
15. Nathan C, Shiloh MU. Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens. Proc Natl Acad Sci U S A. 2000;97:8841–8848.
16. Forrester SJ, Kikuchi DS, Hernandez MS, Xu Q, Griendling KK. Reactive oxygen species in metabolic and inflammatory signaling. Circ Res. 2018;122:877–902.
17. D’Autreux B, Toledano MB. ROS as signalling molecules: Mechanisms that generate specificity in ROS homeostasis. Nat Rev Mol Cell Biol. 2007;8:813–824.
18. Pries AR, Kuebler WM. Normal endothelium. Handb Exp Pharmacol. 2006;176 Pt1:1–40.
19. Jaffe EA. Cell biology of endothelial cells. Hum Pathol. 1987;18:234–239.
20. Hellstrom M, Gerhardt H, Kalen M, Li X, Eriksson U, et al. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol. 2001;153:543–553.
21. van Hinsbergh VW. Endothelium–role in regulation of coagulation and inflammation. Semin Immunopathol. 2012;34:93–106.
22. Feletou M. Integrated systems physiology: From molecule to function to disease. San Rafael (CA): Morgan and Claypool Life Sciences, 2011.
23. Chistiakov DA, Revin VV, Sobenin IA, Orekhov AN, Bobryshev YV. Vascular endothelium: Functioning in normal, changes in atherosclerosis and current dietary approaches to improve endothelial function. Mini Rev Med Chem. 2015;15:338–350.
24. Rafieian-Kopaei M, Setorki M, Doudi M, Baradaran A, Nasri H. Atherosclerosis: Process, indicators, risk factors and new hopes. Int J Prev Med. 2014;5:927–946.
25. Rajendran P, Rengarajan T, Thangavel J, et al. The vascular endothelium and human diseases. Int J Biol Sci. 2013;9:1057–1069.
26. van Jessel SH, Jorens PG, Van Craenenbroeck EM, Conraads VM. The endothelium, a protagonist in the pathophysiology of critical illness: Focus on cellular markers. Biomed Res Int. 2014;2014:985813.
27. Fischer C, Schneider M, Carmeliet P. Principles and therapeutic implications of angiogenesis, vasculogenesis and arteriogenesis. Handb Exp Pharmacol. 2006;176 Pt2:157–212.
28. Fay WP, Garg N, Sunkar M. Vascular functions of the plasminogen activation system. Arterioscler Thromb Vasc Biol. 2007;27:1231–1237.
29. Brown NJ. Blood pressure reduction and tissue-type plasminogen activator release. Hypertension. 2006;47:648–649.
30. Prager GW, Breuss JM, Steurer S, Mihaly J, Binder BR. Vascular endothelial growth factor (VEGF) induces rapid prourokinase (pro-uPA) activation on the surface of endothelial cells. Blood. 2004;103:955–962.

31. Nordi TK, Bode C. Impaired endogenous fibrinolysis in diabetes mellitus: Mechanisms and therapeutic approaches. Semin Thromb Hemost. 2000;26:495–501.

32. Zhang G, Xiang B, Dong A, et al. Biphasic roles for soluble guanylyl cyclase (sGC) in platelet activation. Blood. 2011;118:3670–3679.

33. Gale AJ, Cramer TJ, Rozenshteyn D, Cruz JR. Detailed mechanisms of the inactivation of factor VIIIa by activated protein C in the presence of its cofactors, protein S and factor V. J Biol Chem. 2008;283:16355–16362.

34. Wood JP, Bunce MW, Maroney SA, Tracy PB, Camire RM, Mast AE. Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation. Proc Natl Acad Sci U S A. 2013;110:17838–17843.

35. Lenting PJ, Casari C, Christophe OD, Denis CV. von Willebrand factor: The old, the new and the unknown. J Thromb Haemost. 2012;10:2428–2437.

36. Pearson JD. Endothelial cell function and thrombosis. Baillieres Best Pract Res Clin Haematol. 1999;12:329–341.

37. Hao H, Gabbiani G, Bochaton-Piallat ML. Arterial smooth muscle cell heterogeneity: Implications for atherosclerosis and restenosis development. Arterioscler Thromb Vasc Biol. 2003;23:1510–1520.

38. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev. 2004;84:767–801.

39. Zhu SB, Zhao H, Zou ZZ, Xi EP, Wang RP, Zhang Y. TGF-beta1 induces human aortic vascular smooth muscle cell phenotype switch through PI3K/AKT/ID2 signaling. Am J Transl Res. 2015;7:2764–2774.

40. Chamley-Campbell J, Campbell GR, Ross R. The smooth muscle cell in culture. Physiol Rev. 1979;59:1–61.

41. Young IS, Woodside JV. Antioxidants in health and disease. J Clin Pathol. 2001;54:176–186.

42. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic approach? Nat Rev Drug Discov. 2009;8:579–591.

43. Shukla V, Mishra SK, Pant HC. Oxidative stress in neurodegeneration. Adv Pharmacol Sci. 2011;2011:572634.

44. Haigis MC, Yankner BA. The aging stress response. Mol Cell. 2010;40:333–344.

45. Sakamoto K, Iwasaki K, Sugiyama H, Tsuji Y. Role of the tumor suppressor PTEN in antioxidant responsive element-mediated transcription and associated histone modifications. Mol Biol Cell. 2009;20:1606–1617.

46. Ray PD, Huang BW, Tsuji Y. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal. 2012;24:981–990.

47. Roos G, Messens J. Protein sulfenic acid formation: From cellular damage to redox regulation. Free Radic Biol Med. 2011;51:314–326.

48. Droge W. Free radicals in the physiological control of cell function. Physiol Rev. 2002;82:47–95.

49. Xu S, Touyz RM. Reactive oxygen species and vascular remodelling in hypertension: Still alive. Can J Cardiol. 2006;22:947–951.

50. Gorlach A, Bertram K, Hudecova S, Krizanova O. Calcium and ROS: A mutual interplay. Redox Biol. 2015;5:260–271.

51. Zorov DB, Filburn CR, Klotz LO, Zweier JL, Sollott SJ. Reactive oxygen species (ROS)-induced ROS release: A new phenomenon accompanying induction of the mitochondrial permeability transition in cardiac myocytes. J Exp Med. 2000;192:1001–1014.

52. Vincent A, Crozatier M. Neither too much nor too little: Reactive oxygen species levels regulate drosophila hematopoiesis. J Mol Cell Biol. 2010;12:74–75.

53. Redon J, Oliva MR, Tormos C, Giner V, Chaves J, et al. Antioxidant activities and oxidative stress byproducts in human hypertension. Hypertension. 2003;41:1096–1101.

54. Matoba T, Shimokawa H, Nakashima M, et al. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in mice. J Clin Invest. 2000;106:1521–1530.

55. Breton-Romero R, Lamas S. Hydrogen peroxide signaling in vascular endothelial cells. Redox Biol. 2014;2:529–534.

56. Price DT, Vita JA, Keaney JF Jr. Redox control of vascular nitric oxide bioavailability. Antioxid Redox Signal. 2000;2:919–935.

57. Fukai T, Uschio-Fukai M. Superoxide dismutases: Role in redox signaling, vascular function, and diseases. Antioxid Redox Signal. 2011;15:1583–1606.

58. Touyz RM, Briones AM. Reactive oxygen species and vascular biology: Implications in human hypertension. Hypertens Res. 2011;34:5–14.

59. Griendling KK, Sorescu D, Lassegue B, Uschio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol. 2000;20:2175–2183.

60. Touyz RM. Oxidative stress and vascular damage in hypertension. Curr Hypertens Rep. 2000;2:98–105.

61. Touyz RM, Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev. 2000;52:639–672.

62. Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature: Molecular and cellular mechanisms. Hypertension. 2003;42:1075–1081.

63. Landmesser U, Cai H, Dikalov S, et al. Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension. 2002;40:511–515.

64. Landmesser U, Harrison DG. Oxidative stress and vascular damage in hypertension. Coron Artery Dis. 2001;12:455–461.

65. Diez J, Laviades C, Orbe J, Zalba G, Lopez B, et al. The A1166C polymorphism of the AT1 receptor gene is associated with collagen type I synthesis and myocardial stiffness in hypertensives. J Hypertens. 2003;21:2085–2092.

66. Uschio-Fukai M, Alexander RW. Reactive oxygen species as mediators of angiogenesis signaling: Role of NAD(P)H oxidase. Mol Cell Biochem. 2004;264:85–97.

67. Stone JR, Collins T. The role of hydrogen peroxide in endothelial proliferative responses. Endothelium. 2002;9:231–238.

68. Antunes F, Cadenas E. Cellular titration of apoptosis with steady state concentrations of H(2)O(2): Submicromolar levels of H(2)O(2) induce apoptosis through Fenton chemistry independent of the cellular thiol state. Free Radic Biol Med. 2001;30:1008–1018.

69. Zafari AM, Uschio-Fukai M, Akers M, et al. Role of NADH/NADPH oxidase-derived H2O2 in angiotensin II-induced vascular hypertrophy. Hypertension. 1998;32:488–495.
70. Shimokawa H, Matoba T. Hydrogen peroxide as an endothelium-
derived hyperpolarizing factor. Pharmacol Res. 2004;49:543–549.
71. Fujiki T, Shimokawa H, Morikawa K, et al. Endothelium-derived hydrogen peroxide accounts for the enhancing effect of an angiotensin-converting enzyme inhibitor on endothelium-derived hyperpolarizing factor-mediated responses in mice. Arterioscler Thromb Vasc Biol. 2005;25:766–771.
72. Fujimoto S, Asano T, Sakai M, et al. Mechanisms of hydrogen peroxide-induced relaxation in rabbit mesenteric small artery. Eur J Pharmacol. 2001;412:291–300.
73. Thengchaisri N, Kuo L. Hydrogen peroxide induces endothelium-dependent and -independent coronary arteriolar dilation: Role of cyclooxygenase and potassium channels. Am J Physiol Heart Circ Physiol. 2003;285:H2255–H2263.
74. Burke TM, Wolin MS. Hydrogen peroxide elicits pulmonary arterial relaxation and guanulate cyclase activation. Am J Physiol. 1987;252:H721–H732.
75. Ray R, Murdoch CE, Wang M, et al. Endothelial Nox4 NADPH oxidase enhances vasodilatation and reduces blood pressure in vivo. Arterioscler Thromb Vasc Biol. 2011;31:1368–1376.
76. Cai H, Li Z, Davis ME, Kanner W, Harrison DG, Dudley SC Jr. Akt-dependent phosphorylation of serine 1179 and mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 cooperatively mediate activation of the endothelial nitric-oxide synthase by hydrogen peroxide. Mol Pharmacol. 2003;63:325–331.
77. Rubanyi GM. Vascular effects of oxygen-derived free radicals. Free Radic Biol Med. 1988;4:107–120.
78. Lipinski B. Hydroxyl radical and its scavengers in health and disease. Oxid Med Cell Longev. 2011;2011:809969.
79. Ayala A, Munoz MF, Arguelles S. Lipid peroxidation: Production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid Med Cell Longev. 2014;2014:360438.
80. Ferdinandy P, Schulz R. Peroxynitrite: Toxic or protective in the heart? Circ Res. 2001;88:E12–E13.
81. Ferdinandy P. Peroxynitrite: Just an oxidative/nitrosative stressor or a physiological regulator as well? Br J Pharmacol. 2006;148:1–3.
82. Ronson RS, Nakamura M, Vinten-Johansen J. The cardiovascular effects and implications of peroxynitrite. Cardiovasc Res. 1999;44:47–59.
83. Graves JE, Bates JN, Kooy NW, Lewis SJ. Vasodilator actions of the endothelium-derived relaxing factor L-S-nitrosocysteine in anaesthetized rats are markedly diminished by peroxynitrite. Clin Exp Pharmacol Physiol. 2005;32:1137–1141.
84. Pacher P, Beckman JS, Liautet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev. 2007;87:315–418.
85. Heimlich JB, Speed JS, Bloom CJ, O’Connor PM, Pollock JS, et al. ET-1 increases reactive oxygen species following hypoxia and high-salt diet in the mouse glomerulus. Acta Physiol (Oxf). 2015;213:722–730.
86. Li L, Fink GD, Watts SW, et al. Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in low-renin hypertension. Circulation. 2003;107:1053–1058.
87. Matsuno K, Yamada H, Iwata K, et al. Nox1 is involved in angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADPH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest. 1996;97:1916–1923.
88. Mervaala EM, Cheng ZJ, Tikkanen I, Lapatto R, Nurminen K, et al. Endothelial dysfunction and xanthine oxidoreductase activity in rats with human renin and angiotensinogen genes. Hypertension. 2001;37:414–418.
89. Suzuki H, DeLano FA, Parks DA, et al. Xanthine oxidase activity associated with arterial blood pressure in spontaneously hypertensive rats. Proc Natl Acad Sci U S A. 1998;95:4754–4759.
90. Laakso J, Mervaala E, Himberg JJ, Teravainen TL, Karpunanen H, et al. Increased kidney xanthine oxidoreductase activity in salt-induced experimental hypertension. Hypertension. 1998;32:902–906.
91. Laakso JT, Teravainen TL, Martelin E, Vaskonen T, Lapatto R. Renal xanthine oxidoreductase activity during development of hypertension in spontaneously hypertensive rats. J Hypertens. 2004;22:1333–1340.
136. Zhou MS, Schulman IH, Raji L. Vascular inflammation, insulin resistance, and endothelial dysfunction in salt-sensitive hypertension: Role of nuclear factor kappa B activation. J Hypertens. 2010;28:527–535.

137. Manea A, Manea SA, Gafencu AV, Raicu M. Regulation of NADPH oxidase subunit p22(phox) by NF-kB in human aortic smooth muscle cells. Arch Physiol Biochem. 2007;113:163–172.

138. Pantano C, Reynaert NL, van der Vliet A, Janssen-Heininger YM. Redox-sensitive kinases of the nuclear factor-kappaB signaling pathway. Antioxid Redox Signal. 2006;8:1791–1806.

139. Laurindo FR, Pedro Mde A, Barbeiro HV, et al. Vascular free radical release. ex vivo and in vivo evidence for a flow-dependent endothelial mechanism. Circ Res. 1994;74:700–709.

140. Inoue N, Ramasamy S, Fukai T, Nerem RM, Harrison DG. Shear stress modulates expression of Cu/Zn superoxide dismutase in human aortic endothelial cells. Circ Res. 1996;79:32–37.

141. Kordopati V, Salhi A, Razali R, et al. DES-mutation: System for exploring links of mutations and diseases. Sci Rep. 2018;8:13359.

142. Salhi A, Negrao S, Essack M, Morton MJL, Bougouffa S, et al. DES-TOMATO: A knowledge exploration system focused on Tomato species. Sci Rep. 2017;7:5968.

143. Salhi A, Essack M, Alam T, et al. DES-ncRNA: A knowledgebase for exploring information about human micro and long noncoding RNAs based on literature-mining. RNA Biol. 2017;14:963–971.

144. Bin Raies A, Mansour H, Incitti R, Bajic VB. Combining position weight matrices and document-term matrix for efficient extraction of associations of methylated genes and diseases from free text. PLoS One. 2013;8:e78848.

145. Bin Raies A, Mansour H, Incitti R, Bajic VB. DDMGD: The database of text-mined associations between genes methylated in diseases from different species. Nucleic Acids Res. 2015;43:D879–D886.

146. Dawe AS, Radovanovic A, Kaur M, et al. DESTAF: A database of text-mined associations for reproductive toxins potentially affecting human fertility. Reprod Toxicol. 2012;33:99–105.

147. Essack M, Radovanovic A, Bajic VB. Information exploration system for sickle cell disease and repurposing of hydroxyfasudil. PLoS One. 2013;8:e65190.

148. Essack M, Radovanovic A, Schaefer U, et al. DDEC: Dragon database of genes implicated in esophageal cancer. BMC Cancer. 2009;9:219.

149. Kwofie SK, Radovanovic A, Sundararajan VS, Maqungo M, Christoffels A, Bajic VB. Dragon exploratory system on hepatitis C virus (DESHCV). Infect Genet Evol. 2011;11:734–739.

150. Kwofie SK, Schaefer U, Sundararajan VS, Bajic VB, Christoffels A. HCVPiro: Hepatitis C virus protein interaction database. Infect Genet Evol. 2011;11:1971–1977.

151. Maqungo M, Kaur M, Kwofie SK, et al. DDPC: Dragon database of genes associated with prostate cancer. Nucleic Acids Res. 2011;39:D980–D985.

152. Sagar S, Kaur M, Dawe A, Seshadri SV, Christoffels A, et al. DDESC: Dragon database for exploration of sodium channels in human. BMC Genomics. 2008;9:622.

153. Sagar S, Kaur M, Radovanovic A, Bajic VB. Dragon exploration system on marine sponge compounds interactions. J Chem. 2013;5:11.

154. Kaur M, Radovanovic A, Essack M, et al. Database for exploration of functional context of genes implicated in ovarian cancer. Nucleic Acids Res. 2009;37:D820–D823.

155. Salhi A, Essack M, Radovanovic A, et al. DESM: Portal for microbial knowledge exploration systems. Nucleic Acids Res. 2016;44:D624–D633.

156. Bajic VB, Veronika M, Veladandi PS, et al. Dragon plant biology explorer. A text-mining tool for integrating associations between genetic and biochemical entities with genome annotation and biochemical terms lists. Plant Physiol. 2005;138:1914–1925.

157. Chowdary R, Zhang J, Tan SL, Osborne DE, Bajic VB, Liu JS. PIMiner: A web tool for extraction of protein interactions from biomedical literature. Int J Data Min Bioinform. 2013;7:450–462.

158. Chowdary R, Tan SL, Zhang J, Karnik S, Bajic VB, Liu JS. Context-specific protein network miner—an online system for exploring context-specific protein interaction networks from the literature. PLoS One. 2012;7:e34480.

159. Pan H, Zuo L, Choudhary V, et al. Dragon TF association miner: A system for exploring transcription factor associations through text-mining. Nucleic Acids Res. 2004;32:W230–W234.

160. Essack M, Salhi A, Stanimirovic J, Tifratene F, Raies AB, et al. Literature-based enrichment insights into redox control of vascular biology. Oxid Med Cell Longev. 2019:2019:1769437.

161. Paraskevopoulos MD, Vlachos JS, Karagouni D, et al. DIANA-LncBase v2: Indexing microRNA targets on non-coding transcripts. Nucleic Acids Res. 2016;44:D231–D238.

162. Taverne YJ, Bogers AJ, Dunker DJ, Merkus D. Reactive oxygen species and the cardiovascular system. Oxid Med Cell Longev. 2013;2013:862423.

163. Yang BC, Saldeen TG, Bryant JL, Nichols WW, Mehta JL. Long-term dietary fish oil supplementation protects against ischemia-reperfusion-induced myocardial dysfunction in isolated rat hearts. Am Heart J. 1993;126:1287–1292.

164. Sergiel JP, Martine L, Raederstorff D, Grynberg A, Demaison L. Individual effects of dietary EPA and DHA on the functioning of the isolated working rat heart. Can J Physiol Pharmacol. 1998;76:728–736.

165. Rodrigo R, Korantzopoulos P, Cerecida M, et al. A randomized controlled trial to prevent post-operative atrial fibrillation by antioxidant reinforcement. J Am Coll Cardiol. 2013;62:1457–1465.

166. Abywardena MY, Patten GS. Role of omega-3 long-chain polyunsaturated fatty acids in reducing cardio-metabolic risk factors. Endocr Metab Immune Disord Drug Targets. 2011;11:232–246.

167. Weber P, Raederstorff D. Triglyceride-lowering effect of omega-3 LC-polyunsaturated fatty acids—a review. Nutr Metab Cardiovasc Dis. 2000;10:28–37.

168. Johansson I, Monsen VT, Pettersen K, et al. The marine n-3 PUFA DHA evokes cytoprotection against oxidative stress and protein misfolding by inducing autophagy and NFE2L2 in human retinal pigment epithelial cells. Autophagy. 2015;11:1636–1651.

169. Farago N, Feher LZ, Kitajka K, Das UN, Puskas LG. MicroRNA profile of polyunsaturated fatty acid treated glioma cells reveal apoptosis-specific expression changes. Lipids Health Dis. 2011;10:173.

170. Mandal CC, Ghosh-Choudhury T, Dey N, Choudhury GG, Ghosh-Choudhury N. miR-21 is targeted by omega-3 polyunsaturated fatty acids and modulate carcinogen-directed non-coding microRNA signatures in rat colon. Carcinogenesis. 2009;30:2077–2084.
172. Zhu Y, Yan Y, Principe DR, Zou X, Vassilopoulos A, Gius D. SIRT3 and SIRT4 are mitochondrial tumor suppressor proteins that connect mitochondrial metabolism and carcinogenesis. Cancer Metab. 2014;2:15.

173. Lang A, Grether-Beck S, Singh M, et al. MicroRNA-15b regulates mitochondrial ROS production and the senescence-associated secretory phenotype through sirtuin 4/SIRT4. Aging (Albany NY). 2016;8:484–505.

174. Qin B, Liu J, Liu S, Li B, Ren J. MiR-20b targets AKT3 and modulates vascular endothelial growth factor-mediated changes in diabetic retinopathy. Acta Biochim Biophys Sin (Shanghai). 2016;48:732–740.

175. Wright GL, Maroulakou IG, Eldridge J, et al. VEGF stimulation of mitochondrial biogenesis: Requirement of AKT3 kinase. FASEB J. 2008;22:3264–3275.

176. Bavia L, Mosimann AL, Aoki MN, Duarte Dos Santos CN. A glance at subgenomic flavivirus RNAs and microRNAs in flavivirus infections. Virol J. 2016;13:84.

177. Soundravally R, Hoti SL, Patil SA, et al. Association between pro-inflammatory cytokines and lipid peroxidation in patients with severe dengue disease around defervescence. Int J Infect Dis. 2014;18:68–72.

How to cite this article: Obradovic M, Essack M, Zafarić S, et al. Redox control of vascular biology. BioFactors. 2020;46:246–262. https://doi.org/10.1002/biof.1559